WVU Medicine Fairmont Medical Center participates in National Donate Life Month
FAIRMONT, W.Va. (WBOY) — April is Donate Life month, and with the help of WVU Medicine, the Center for Organ Recovery and Education (CORE) is helping inform the public on the life-changing impacts an organ donation can make.
On Thursday, WVU Medicine Fairmont Medical Center raised its 'Donate Life' flag to gain awareness of Donate Life Month. Currently, more than 100,000 people are waiting for an organ transplant, and the current wait time is roughly four years once an individual is placed on the waiting list.
CORE Volunteer Advocate Lori Batteli spoke at the event on Thursday, as she is also a recipient of a kidney donation.
UHC honors donors and their families for National Donate Life Month
After having multiple kidney infections, Batteli had an infection that turned septic, and her kidneys were damaged by 50%. A stomach bug had put Batteli in the ER on Christmas Eve, where she was told her kidneys had stopped functioning, leading her to start dialysis treatments and being placed on the transplant waitlist.
'I was on the list for about three and a half years. I got my kidney in June of 2019. I got a phone call at four in the morning, and I went out, got it, and immediately I just felt amazing afterwards. I don't know if it was just the high from surgery, but I just felt so much better, fluid was coming off of me, my kidney values were going down, and it was just everything. And I started to get my life back together,' said Batteli.
You can learn more about how to become a donor by visiting Donate Life's website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
LivaNova completes epilepsy treatment study of VNS Therapy
LivaNova has completed the CORE-VNS study, assessing outcomes via real-world evidence on the use of the VNS Therapy device in over 800 individuals with epilepsy. The study's final 36-month data confirms the therapy's effectiveness on severe focal seizures in paediatric and adult patients with drug-resistant epilepsy (DRE), showing early and sustained benefits. This open-label, long-term study enrolled participants from 61 sites around the world. The majority of the subjects, across all age groups, reported focal onset seizures with impaired awareness (FIA) as their most disabling seizure type. According to the study's data, for children aged four to 18, there was an 87% median reduction in FIA motor seizures at 36 months. Inclusive of adults, 34% of subjects with FIA motor seizures achieved 100% seizure minimisation, with an overall median decrease of 80%. Similarly, focal to bilateral tonic-clonic (FBTC) seizures saw a median reduction of 100% in children, and 49% of all participants with FBTC seizures reported complete seizure minimisation at their three-year study visit. VNS Therapy's effectiveness was observed as early as three months post-implantation, with further substantial decreases in both FIA and FBTC seizures observed at subsequent 12-, 24-, and 36-month visits. Notably, the CORE-VNS study claimed to have a high patient retention rate of 82% over the three-year follow-up period. LivaNova noted that VNS Therapy is an add-on treatment designed to decrease the seizure frequency in individuals aged four and above with DRE and partial-onset seizures. Involving an outpatient procedure, the implantation of this therapy does not involve skull penetration. The outcomes of the 36-month CORE-VNS study are set to be published later in the year. LivaNova Global Medical Affairs vice-president Kathryn Nichol said: 'LivaNova is deeply committed to advancing epilepsy research and in every study of VNS Therapy to date, we continue to see that effectiveness can be achieved early and continue to improve month by month and visit by visit. This remained true over the course of three years in CORE-VNS.' Last year, the company reported positive predictive outcomes from the OSPREY study of the aura6000 hypoglossal nerve stimulator system for treating obstructive sleep apnoea. "LivaNova completes epilepsy treatment study of VNS Therapy" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
WVU Medicine Princeton Community Hospital breaks ground on PCH Bluefield campus
BLUEFIELD, WV (WVNS) – WVU Medicine continues to expand with the breaking of ground for the new Bluefield campus of Princeton Community Hospital. Located on Southview Drive, the $25 million facility will offer state-of-the-art care to residents in the area. The location will be home to the Bluefield Emergency Department and PCH Behavioral Health Center, and the expansion itself is part of an effort by WVU Medicine to offer comprehensive access and care to patients no matter where they are in the state, according to Princeton Community Hospital President and CEO, Karen Bowling.'One reason WVU Medicine has expanded is we want to make sure we are serving the entire community and that it is a comprehensive level of care,' she said. 'If you think about it, we're on the same medical record. Whether you're in Princeton or you're in Bluefield, whether you need to go to Ruby to have a bone marrow transplant – we're all on the same medical record.'Bowling said the expansion is about communities, families, and serving the region as well as the state. 'As someone who grew up in this region, I know firsthand how much this investment means,' she continued. 'This project is about more than bricks and mortar; it's about giving our families, friends, and neighbors access to the kind of care they deserve, right here at home. WVU Medicine is making a promise to this region, and I'm proud to be part of delivering on that promise.' WVU Medicine President & CEO, Albert Wright reiterated the importance of widespread coverage under a single umbrella as it pertains to patient care. 'This project exemplifies WVU Medicine's unwavering investment in delivering high-quality, accessible care to West Virginians,' he said. 'By expanding services and upgrading facilities, like here at the Bluefield Campus, we're not only enhancing patient care, but we're also reinforcing our long-term commitment to advancing health outcomes in southern West Virginia.'Features of the Bluefield campus will include: The new emergency department (ED) will include: 20 exam rooms, including two rooms designed for psychiatric intake Two resuscitation rooms and two triage rooms OB-ready and trauma rooms Centralized care team support stations Dedicated patient and ambulance entrances Diagnostic Radiology — two radiology rooms Computed Tomography (CT) — one CT scanner Magnetic Resonance Imaging (MRI) — one MRI scanner (a new service for Bluefield) Ultrasound — two ultrasound rooms (a new service for Bluefield) Guest speakers and live music were part of the groundbreaking celebration as guests got their first look at plans for the new facility. PCH plans to officially open the doors to its Bluefield campus in the Fall of 2027, as the provider hopes to further extend the scope of patient accessibility and care. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
4 days ago
- Business Wire
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than 800 people with epilepsy treated with VNS Therapy™ worldwide. With the clinical study report (CSR) now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy (DRE) and demonstrate early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures. With the clinical study report now complete, the final 36-month data further validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy and demonstrate early and lasting outcomes. Share 'It is critically important to conduct long-term, real-world studies like CORE-VNS, and it is pleasing to see these clinically meaningful and durable results demonstrating the effectiveness of VNS Therapy for people living with drug-resistant epilepsy,' said Arjune Sen, Professor of Global Epilepsy at The University of Oxford and Consultant Neurologist at Oxford University Hospitals NHS Foundation Trust. Prof. Sen is also coordinating investigator for the CORE-VNS study. The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy, in pediatric and adult patients, and expands upon LivaNova's presentation of interim 24-month data evaluating the effectiveness of VNS Therapy in children ages 4 to 18 years old with focal onset seizures at the American Epilepsy Society's annual conference in December 2024. 1 Within the full 36-month analysis, the greatest proportion of patients at all ages reported focal onset seizures with impaired awareness (FIA) to be their most disabling seizure type. CORE-VNS study data demonstrate the impact of VNS Therapy, including: In children 4 to 18 years old, FIA motor seizures, for example, reduced by a median of 87% at 36 months. Including adults, 34% of people with FIA motor seizures reported 100% seizure reduction (freedom from these seizures over the three months prior to their three-year study visit), with an overall median reduction of 80%. In children 4 to 18 years old, focal to bilateral tonic-clonic (FBTC) seizures reduced by a median of 100% at 36 months. Including adults, 49% of people with FBTC seizures reported 100% seizure reduction at the three-year study visit, with an overall median reduction of 95%. The effectiveness of VNS Therapy was noted as early as three months after implantation, followed by further substantial reduction noted in both FIA and FBTC seizures at the 12-, 24-, and 36-month study visits. Unlike many long-term follow-up studies on DRE, CORE-VNS had a high patient-retention rate throughout the three years of follow-up (82%). 'LivaNova is deeply committed to advancing epilepsy research and in every study of VNS Therapy to date, we continue to see that effectiveness can be achieved early and continue to improve month by month and visit by visit. This remained true over the course of three years in CORE-VNS,' said Kathryn Nichol, Ph.D., Vice President Global Medical Affairs, LivaNova. 'Further, CORE-VNS confirms that VNS Therapy is effective for the most severe focal seizures in pediatric and adult patients. Not all seizures are created equal—this is why evaluating severe focal seizures that may have a larger impact on quality of life and outcomes in people with drug-resistant epilepsy is so important.' CORE-VNS is the largest prospective study of VNS Therapy ever conducted worldwide. The full, 36-month CORE-VNS study results will be published later this year. "The strong outcomes from the CORE-VNS study bolster our efforts to narrow the DRE treatment gap, increase access to care, and drive awareness of surgical therapies for this significantly under-addressed patient population,' said Stephanie Bolton, LivaNova President, Global Epilepsy. About CORE-VNS CORE-VNS is a real-world, long-term, open-label study focused on the outcomes of VNS Therapy™ in people diagnosed with drug-resistant epilepsy (DRE). Enrolling more than 800 people from 61 worldwide sites, the study is the most comprehensive assessment of the effectiveness of VNS Therapy to date and provides modern insights into the global use of VNS Therapy in the management and control of seizures. Adverse events in the CORE-VNS study were typical of those reported in the product labeling and experienced following placement of a VNS Therapy device. The most commonly reported (>5%) adverse events overall included respiratory, thoracic, and mediastinal disorders (dysphonia, dyspnea, cough) and general disorders/administration site conditions. See important safety information at About VNS Therapy for Epilepsy VNS Therapy™ is clinically proven safe and effective as an add-on treatment to reduce the frequency of seizures in adults and children as young as 4 years old with drug-resistant epilepsy and partial onset seizures. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects approximately one in three people with epilepsy. Unlike some other surgical treatment options for people with drug-resistant epilepsy, VNS Therapy implantation involves an outpatient procedure and does not require penetration of the skull. Outside the United States, the VNS Therapy indications for use may vary. For more information, visit References About LivaNova LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit Safe Harbor Statement This news release contains 'forward-looking statements' concerning the Company's goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the CORE registry and VNS Therapy™ for epilepsy. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
